Key result
Among 150 heart disease patients, overall awareness of smoking cessation pharmacotherapies was low, with only 32.2% aware of nicotine patches and 7.4% aware of varenicline.
Why the study?
Smoking is linked to heart problems, highlighting the need for smoking cessation awareness in patients with heart disease and established vascular disease for secondary prevention.
Cohort (n=150)
Yes
There is a significant lack of awareness regarding smoking cessation aids among heart disease patients, highlighting a critical gap in secondary cardiovascular prevention strategies.
Answers are grounded in this paper and cite their sources.
Supports smoking cessation emphasis in vascular disease secondary prevention; leaves open targeted strategies for rising global smoking rates.
Over one million people are smoking worldwide and the total numbers is expected to increase each year [1]. Several studies have shown a relation between smoking and heart problems, which highlight special consideration in smoking cessation awareness in heart disease patients with established vascular disease as a secondary prevention.
No takes yet. Share an insight, caveat, or question.
Hanin et al. (2022) conducted a cohort in Heart disease (n=150). Smoking cessation products was evaluated on Awareness of smoking cessation products and its usage. Among 150 heart disease patients, overall awareness of smoking cessation pharmacotherapies was low, with only 32.2% aware of nicotine patches and 7.4% aware of varenicline.
Synapse has enriched 10 related papers. Consider them for comparative context: